Table of contents
December 2008 Volume 5 No 12
Research Highlights
Raised levels of IGF-I increase the risk of developing prostate cancer
638Suprapubic drainage is a suitable alternative to catheterization after prostatectomy
638Excess weight increases risk of death from prostate cancer
638Genetic polymorphism identified in men with lifelong premature ejaculation
639Tamsulosin improves clearance of renal calculi fragments after shockwave lithotripsy
639Black men in the UK have an elevated risk of developing prostate cancer
640CT urography accurately detects bladder cancer in patients with hematuria
640Tacrolimus ointment is a safe adjuvant treatment for lichen sclerosus in boys
641Practice Points
Can imaging be used to assess treatment success after ablation of renal tumors?
642doi:10.1038/ncpuro1213 | Full Text | PDF (131K)
Does adjuvant vitespen prevent recurrence in patients with locally advanced kidney cancer?
644doi:10.1038/ncpuro1256 | Full Text | PDF (138K)
Does antibiotic prophylaxis prevent renal scarring in children with vesicoureteral reflux?
646doi:10.1038/ncpuro1245 | Full Text | PDF (134K)
Should patients with localized prostate cancer receive primary androgen deprivation therapy?
648doi:10.1038/ncpuro1233 | Full Text | PDF (138K)
What is the current status of second-line chemotherapy for castration-resistant prostate cancer?
650doi:10.1038/ncpuro1232 | Full Text | PDF (205K)
Viewpoints
A unifying strategy for clinical trials in rare urological malignancy
652The management of uncommon urological malignancies is rarely based on evidence from prospective trials, and ad hoc treatment by individual clinicians who seldom encounter the cancer is not ideal for the patient. In this article, Nicholson identifies key issues in developing a trial strategy for treating rare urological malignancies.
doi:10.1038/ncpuro1257 | Full Text | PDF (132K)
Expediting the availability of drugs for US patients with cancer
654In this Viewpoint, the authors discuss the FDA's strategies for increasing access to new medicines for patients with serious or life-threatening illnesses. The article describes the currently available access mechanisms, and highlights the FDA's planned regulation revisions for expanding access.
doi:10.1038/ncpuro1255 | Full Text | PDF (187K)
Reviews
Sacral neuromodulation for urinary retention
657Sacral neuromodulation (SNM) has been investigated as a treatment for a range of refractory lower urinary tract disorders. In this Review, Kessler and Fowler discuss developments in SNM techniques and technology, assess patient outcomes, and consider potential mechanisms of action for this therapy.
doi:10.1038/ncpuro1251 | Full Text | PDF (488K)
Concurrent urinary tract infection and stone disease: pathogenesis, diagnosis and management
668Urinary tract stones and urinary tract infection are strongly associated. In this Review, Thomas and Tolley describe the pathogenesis, diagnosis and management of infection stones, and also the management of patients who develop infections as a consequence of stone disease.
doi:10.1038/ncpuro1254 | Full Text | PDF (494K)
Molecular biomarkers for urothelial carcinoma of the bladder: challenges in clinical use
676The integration of molecular biomarkers into prediction models has the potential to improve the management of urothelial carcinoma of the bladder. Bolenz and Lotan outline the search for candidate biomarkers in this disease, and discuss the obstacles to their use in routine clinical practice.
doi:10.1038/ncpuro1259 | Full Text | PDF (333K)
Case Studies
A case of staghorn stones in a kidney with an ileal ureter treated by percutaneous nephrolithotomy
686In this Case Study, Gao et al. present a 59-year-old man with complete staghorn calculi who had previously undergone ileal ureteral replacement. The patient was successfully treated with percutaneous nephrolithotomy. The authors emphasize the essential role of CT urography in diagnosis and treatment planning in such complex cases.
doi:10.1038/ncpuro1229 | Full Text | PDF (296K)
Presentation and management of a patient with subcutaneous metastatic transitional cell carcinoma of the bladder
691This Case Study describes a 60-year-old woman who presented with an enlarging subcutaneous lesion on her right flank, 6 months after having undergone treatment for transitional cell carcinoma (TCC) of the bladder. The article highlights that rare cutaneous TCC metastases can mimic common benign and inflammatory processes, and the authors suggest treatment options for such patients.
doi:10.1038/ncpuro1253 | Full Text | PDF (350K)
